Dean, James P <br/><br/>
Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.  [electronic resource] 

 -  The Journal of clinical endocrinology and metabolism  May 2013 
 - E820-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1945-7197 
<br/><br/><label>Standard No.: </label>10.1210/jc.2012-3856  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--complications<br/>Androgen Antagonists--administration & dosage<br/>Anilides--administration & dosage<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Body Mass Index<br/>Cohort Studies<br/>Goserelin--administration & dosage<br/>Humans<br/>Insulin--blood<br/>Insulin Resistance<br/>Insulin-Like Growth Factor Binding Protein 1--blood<br/>Male<br/>Neoadjuvant Therapy<br/>Nitriles--administration & dosage<br/>Obesity--complications<br/>Prostatectomy<br/>Prostatic Neoplasms--complications<br/>Receptor, IGF Type 1--antagonists & inhibitors<br/>Risk<br/>Secondary Prevention<br/>Somatomedins--analysis<br/>Tosyl Compounds--administration & dosage<br/>United States--epidemiology